We are live on ! Find out more
LVTX

LAVA Therapeutics
LVTX

Delisted

LVTX was delisted on the 20th of November, 2025.

Back to rankings

14 hedge funds and large institutions have $8.47M invested in LAVA Therapeutics in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.1% less ownership

Funds ownership: 21.86% → 21.75% (-0.1%)

7% less funds holding

Funds holding: 15 → 14 (-1)

27% less capital invested

Capital invested by funds: $11.7M → $8.47M (-$3.2M)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
14
Holders Change
-1
Holders Change %
-6.67%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
2
Closed
1
Calls
$25K
Puts
–
Net Calls
+$25K
Net Calls Change
-$10K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$179

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$29.3K
2
HF
HRT Financial
New York
-$21K
3
Simplex Trading
Simplex Trading
Illinois
-$837

LVTX Hedge Fund Activity: Q3 2023 in Review

14 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q3 2023, worth a combined $8.47M — down 27% from $11.7M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of LVTX and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.

The largest buyer was Morgan Stanley, adding an estimated $179. The largest seller was Millennium Management, cutting an estimated $29.3K.

  • 14 institutional investors held LAVA Therapeutics (LVTX) as of Q3 2023, down from 15 in Q2 2023.
  • Funds reported $8.47M of LAVA Therapeutics stock for Q3 2023, down 27% quarter-over-quarter.
  • 0 funds opened new LAVA Therapeutics positions in Q3 2023 and 1 closed out, a net change of -1 holder.
  • The largest LAVA Therapeutics buyer in Q3 2023 was Morgan Stanley, an estimated $179 added.
  • The largest LAVA Therapeutics seller in Q3 2023 was Millennium Management, an estimated $29.3K sold.

Based on aggregated 13F filings for Q3 2023.